Chardan lowered the firm’s price target on Crispr Therapeutics (CRSP) to $123 from $153 and keeps a Buy rating on the shares after the company reported FY22 results, stating that exa-cel launch prep "appears to be progressing well." The firm, which updated its model for 2022 financials, a more conservative valuation of the I/O cell therapy platform, and a slower ramp for exa-cel, said it continues to believe Vertex’s (VRTX) global network and commercial expertise should help position exa-cel for a successful launch.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRSP:
- CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
- Crispr Therapeutics options imply 4.4% move in share price post-earnings
- Crispr Therapeutics options imply 4.9% move in share price post-earnings
- CRISPR Therapeutics to Participate in Upcoming Investor Conferences
- Crispr Therapeutics price target lowered to $70 from $100 at JMP Securities